#USA #New York #Faruqi & Faruqi #Josh Wilson #Rocket Pharmaceuticals

Investor Deadline Approaching: Legal Actions in Focus

Faruqi & Faruqi, LLP, a prominent securities law firm with extensive experience in investor protection, is currently investigating potential legal claims on behalf of investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). The investigations center on allegations regarding misleading information shared with investors and failures to disclose material facts that significantly affected stock values.

Background on Rocket Pharmaceuticals

Rocket Pharmaceuticals is known for its innovative approaches to gene therapy, particularly in treating rare genetic diseases. However, recent developments have raised serious concerns regarding the company’s clinical trial processes and communication practices. Between February 27, 2025, and May 26, 2025, many investors reportedly suffered losses exceeding $50,000 sustained from investing in Rocket shares.

On May 27, 2025, Rocket announced that the Food and Drug Administration (FDA) had placed a clinical hold on its RP-A501 Phase 2 pivotal study. This announcement followed tragic reports of Serious Adverse Events (SAEs), including a patient death linked to the ongoing trial. Critically, Rocket had altered the clinical trial protocol to introduce an experimental immunomodulatory agent but failed to adequately inform investors about these changes.

The Allegations

The complaint lodged against Rocket Pharmaceuticals alleges that, while the company continued to paint a positive picture to shareholders, it concealed key information that misled investors. Specifically, it is claimed that Rocket knew about the risks posed by SAEs but did not disclose this to its investors. Consequently, shareholders were induced to buy stocks at inflated prices, only to face significant losses when the truth came to light.

Rocket’s stock plummeted from $6.27 to $2.33 on the trading day following the FDA announcement, marking a staggering 37% decline. This sharp drop further emphasizes the potential fallout from the firm's handling of both clinical trial updates and investor communications.

Call to Action for Investors

James (Josh) Wilson, a partner at Faruqi & Faruqi, underscores the urgency for affected investors to act swiftly. With the deadline for filing as lead plaintiff in a class action lawsuit set for August 11, 2025, investors are strongly encouraged to reach out for a consultation. The lead plaintiff represents the class members in litigation, thus playing a pivotal role in guiding the legal process on behalf of all affected parties.

Individuals who believe they may qualify as lead plaintiffs, or who simply want to know more about their legal rights, are advised to contact Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi is also interested in gathering information from whistleblowers, current and former employees, and anyone else with insights into Rocket’s practices.

Conclusion

The situation surrounding Rocket Pharmaceuticals serves as a stark reminder of the risks inherent in investing, particularly in sectors driven by clinical trials and regulatory reviews. It speaks to the importance of transparency and accurate communication in maintaining investor trust and protecting their interests. As the investigation unfolds, keeping a close eye on updates from legal representatives is crucial for those impacted by these developments. For further information on this ongoing class action, visit Faruqi & Faruqi’s official website or follow them on various social media platforms for timely updates.

• ---

Attorney advertising, prior results do not guarantee a similar outcome. All communications are confidential.